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oRIGINAL ARTICLE
Introduction: Local-regional control (LRC) rates for non-small 
cell lung cancer after chemoradiotherapy were studied (using two 
different definitions of LRC) for the association between LRC and 
survival.
Methods: Seven legacy Radiation Therapy oncology Group trials 
of chemoradiotherapy for locally advanced non-small cell lung can-
cer were analyzed. Two different definitions of LRC were studied: (1) 
freedom from local progression (FFLP-LRC), the traditional Radiation 
Therapy oncology Group methodology, in which a failure is intratho-
racic tumor progression by World Health organization criteria; and (2) 
response-mandatory (strict-LRC), in which any patient not achieving 
at least partial response was considered to have failure at day 0. Testing 
for associations between LRC and survival was performed using a Cox 
multivariate model that included other potential predictive factors.
Results: A total of 1390 patients were analyzed. The LRC rate at 
3 years was 38% based on the FFLP-LRC definition and 14% based 
on the strict-LRC definition. Performance status, concurrent chemo-
therapy, and radiotherapy dose intensity (biologically equivalent dose) 
were associated with better LRC (using either definition). With the 
strict-LRC definition (but not FFLP-LRC), age was also important. 
There was a powerful association between LRC and overall survival 
(p  0.0001) on univariate and multivariate analyses. Age, perfor-
mance status, chemotherapy sequencing, and biologically equivalent 
dose were also significantly associated with survival. Histology and 
gender were also significant if the strict-LRC model was used.
Conclusions: LRC is associated with survival. The definition of 
LRC affects the results of these analyses. A consensus definition 
of LRC, incorporating functional imaging and/or central review, is 
needed, with the possibility of using LRC as a surrogate end point 
in future trials.
Key Words: Non-small cell lung cancer, Local control, 
Chemoradiotherapy.
(J Thorac Oncol. 2012;7: 716–722)
It is axiomatic that cure of cancer cannot be achieved without control of the primary tumor site (local control). There have 
been many studies investigating the relationship between local 
control and survival in a variety of malignancies, including 
non-small cell lung cancer (NSCLC).1 Most of these studies 
showed that cancer patients who have local control live longer 
than those who do not have local control.
A challenge in studying local control in stage III unre-
sectable NSCLC is that it is difficult to assess local tumor 
status in this disease. With rare exceptions, these cancers are 
not evaluable on clinical office examination. Interpretation 
of chest radiography and computed tomography (CT) is 
hindered by extensive radiation-induced inflammation and 
fibrosis, which can mimic persistently active or recurrent/
progressive tumor.
Data show that tumor control and survival has 
improved with the use of chemoradiotherapy when com-
pared with radiotherapy alone.2 Nevertheless, the reported 
rate of local-regional control (LRC) in scientific studies has 
varied widely, despite relatively similar radiotherapy tech-
niques and chemotherapy regimens. This likely depends 
on the means with which LRC is assessed and analyzed. 
For example, an early Radiation Therapy oncology Group 
(RToG) study of radiotherapy alone for NSCLC suggested 
that with an x-ray therapy dose of 60 Gy continuous course, 
2-year LRC was above 60%.3 In contrast, a randomized 
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trial by LeChevalier—in which postradiotherapy bronchos-
copy/biopsy was routinely performed—suggested that true 
LRC was only achieved in about 20% of patients.4 No other 
major, large randomized trial in unresectable stage III lung 
cancer required an attempt at postradiotherapy pathologic 
assessment of local control.
Because radiotherapy is a local-regional anticancer 
treatment, it is important to assess LRC in studies that involve 
radiotherapy even if pathologic assessment is not feasible.
We performed several analyses of the RToG database 
to examine the probability of LRC after chemoradiotherapy. 
our study specifically evaluates two different definitions 
of LRC: (1) the “traditional” RToG measure of LRC, also 
referred to as freedom from local progression (FFLP-LRC) 
and (2) a more rigorous definition of LRC which requires 
objective local-regional tumor response in addition to FFLP, 
similar to the definition of LRC often used in studies of head 
and neck cancer (strict-LRC). We hypothesized that there 
would be significant differences in the analyses depending on 
how LRC is defined.
MATERIALS AND METHODS
This is a retrospective analysis of prospective data col-
lected on patients treated with chemoradiotherapy in prospec-
tive RToG protocols from 1988 through 2002. All patients 
eligible for analysis were included.
The studies analyzed were as follows:
RToG 88-08 (Phase III trial: chemo-RT arm only)•  5: This 
consisted of induction cisplatin/vinblastine chemother-
apy followed by definitive radiotherapy (60 Gy).
RToG 90-15•  6: Phase I/II trial of concurrent cisplatin/vin-
blastine with definitive bid radiotherapy (69.6 Gy)
RToG 91-06•  7: Phase I/II trial of concurrent cisplatin/
etoposide with definitive bid radiotherapy (69.6 Gy)
RToG 92-04•  8: Phase IIR trial; one arm was the same 
treatment as in RToG 91-06, while the second arm was 
induction cisplatin/vinblastine followed by concurrent 
cisplatin/radiotherapy (63 Gy).
RToG 93-09•  9: Phase III study of immediate concurrent 
chemoradiotherapy (cisplatin/etoposide/RT [61 Gy]) 
with or without surgical resection (potentially operable 
IIIA only)—for this analysis only the patients random-
ized to no surgery were included.
RToG 94-10•  10: Phase III trial comparing chemo-RT 
as given in RToG 88-08 versus immediate concurrent 
chemo-RT (cisplatin/vinblastine/RT [63 Gy]) versus the 
RToG 91-06 regimen.
RToG 98-01•  11: Phase III trial of induction chemotherapy 
(carboplatin/paclitaxel) followed by concurrent chemo-
radiotherapy (carboplatin/paclitaxel/bid RT [69.6 Gy]) 
with or without amifostine.
Radiotherapy techniques and doses were similar for 
all of these studies. Specifically, all of these studies included 
elective nodal irradiation to the entire mediastinum and in 
some cases the supraclavicular and/or contralateral hilar 
nodes to 45 Gy. These comprehensive radiotherapy treat-
ment fields were then followed by a boost to gross disease 
to at least 60 Gy (maximum 69.6 Gy in 1.2 Gy bid frac-
tionation). “High technology” forms of modern radio-
therapy such as intensity modulated radiation therapy, 
image-guided radiation therapy, adaptive radiotherapy, 
respiratory-gated radiotherapy, or air/tissue inhomogeneity 
corrected radiotherapy dosimetry were not used. CT-based 
simulation/planning and three-dimensional conformal 
planning and delivery of radiotherapy were allowed but not 
routinely used and certainly not required in any of these 
studies. Unfortunately, however, RToG did not collect 
detailed information about the type of simulation and treat-
ment planning that was used in the patients in these stud-
ies (as opposed to three-dimensional conformal-specific 
RToG studies 93-11 and 01-17, which are not included in 
this analysis). The studies included in this analysis required 
that the prescription dose (60–69.6 Gy, depending on the 
exact study) be specified to isocenter, rather than renormal-
ization of dose to a peripheral isodose.
Instructions for the assessment for tumor control were 
consistent among these studies. Specifically, all patients were 
required to undergo a postradiotherapy CT scan of the chest 
(including liver or adrenals) approximately 6 months after 
completing radiotherapy, then every 6 months for 2 years, and 
then annually. Additional CT scans were allowable at other 
intervals as clinically indicated, for example, if there was 
clinical suspicion for recurrence or progression. It was rec-
ommended that these CT scans be performed both with and 
without contrast and that CT slices be 5 mm or smaller. Bone 
scan and/or head CT/magnetic resonance imaging scanning 
in follow-up was only performed if metastatic disease was 
suggested by clinical evaluation. Positron emission tomogra-
phy (PET) scans were not used for staging or posttreatment 
assessment in this study (patients in this analysis were treated 
between 1988 and 2002).
Local-regional failure was determined by the individual 
site and the radiation oncology physician investigators, who 
were charged with determining whether an “event” (progres-
sion of lung cancer) has occurred, and if so if it was in-field, at 
the edge of the field, or out of field. Any one of the following 
events constituted a local-regional failure:
1. Enlargement by >25% in the bidimensional product of 
two dimensions of a measurable index (pretreatment) 
lesion.
2. For a nonmeasurable lesion, estimated enlargement by 
>25% of tumor bulk, after taking into account postradia-
tion pneumonitis/fibrosis.
3. The development of severe tumor-related local-regional 
complications such as postobstructive pneumonia 
and/or hemoptysis was also considered as criteria for 
local-regional failure if these clinical events could not 
be attributed to radiation toxicity and/or intercurrent 
disease.
4. The appearance of a new malignant lesion within the 
radiation field or at the edge of the radiation field.
5. Positive biopsy and/or surgical specimen after radio-
therapy showing viable non-small cell lung carcinoma 
after radiotherapy.
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It was not necessary to have more than one posttreat-
ment CT scan to document local-regional failure. Biopsy 
confirmation of local-regional failure was also not required 
and was in fact rarely performed in these studies. All of the 
above assessments (other than biopsy results) were based on 
an assessment performed by the local (site) investigator radi-
ation oncologist. These assessments were done at the time of 
posttreatment follow-up visits/scans and reported to RToG 
headquarters on data collection forms. These assessments 
thus represent “prospective” assessments of LRC by the 
local radiation oncologists/investigators, performed in most 
cases before patient death or last follow-up. Retrospective 
reanalysis by RToG headquarters was not performed, and 
actual CT images were not collected by RToG.
Supraclavicular nodal metastases were not common, but 
when they occurred, they were considered local-regional fail-
ure in those cases where the supraclavicular fossa was part of 
the original AP-PA field(s). Malignant effusions (pleural and/
or pericardial) were considered distant metastases rather than 
local-regional failure.
For analysis of strict-LRC, the initial response assess-
ment was based on the CT scan performed approximately 6 
months after radiotherapy, except in cases when there was 
clear progression before 6 months.
LRC was assessed using two different methodologies, 
described below:
1. Freedom from local-regional progression (FFLP—for 
this article, the abbreviation FFLP-LRC will be used): 
With this definition, which is the traditional RToG 
definition of LRC for lung cancer, all patients are pre-
sumed to have LRC at day 0 (date of randomization). 
Subsequently, the development of progressive lung can-
cer within or adjacent to the radiotherapy field (includ-
ing regional nodes) was considered to be local-regional 
failure. Patients were censored at the date of death if 
they died of distant metastases or died without docu-
mented progressive cancer; they were censored at the 
date of last follow-up if they were still alive with no evi-
dence of local-regional failure.
2. Response-mandatory (strict) Local-regional con-
trol (strict-LRC): With this more stringent definition, 
patients are not considered to have LRC unless they 
achieve at least a partial response of their primary 
tumor by imaging ([mtequ]50% reduction in the prod-
uct of two dimensions of the dominant tumor lesion). 
Patients who do not achieve objective response are 
considered to have suffered local-regional failure at 
day 0 (date of randomization). Patients who do achieve 
objective response are then evaluated similarly to 
FFLP-LRC (as above). The development of progres-
sive lung cancer within or adjacent to the radiotherapy 
field after a response was considered to be local-re-
gional failure at the date of progression. The distinc-
tion of whether progressive lung cancer was considered 
to be within or adjacent to the radiotherapy field was 
determined by the individual site investigator. Central 
review of  posttreatment imaging was not performed. 
Patients were censored at the date of death if they died 
of distant metastases or died without documented pro-
gressive cancer; they were censored at the date of last 
follow-up if they were still alive with no evidence of 
local-regional failure.
LRC rates were analyzed using the Kaplan-Meier 
method. Factors potentially predictive for LRC were assessed, 
including patient-related factors (age [70 versus 70], gen-
der [female versus male], and Karnofsky performance status 
{KPS} [7080 versus 90100]), tumor-related factors (stage 
[IIA/IIIA versus IIIB] and histology [nonsquamous versus 
squamous]), and treatment-related factors (chemotherapy 
sequencing and biologically equivalent dose [BED]). LRC 
was modeled multivariately using the Cox proportional haz-
ards method to find associations with these potentially predic-
tive factors.
Finally, for each methodology, an assessment of the 
relationship between LRC and survival was performed. For 
these analyses, LRC was analyzed in a binary fashion (no pro-
gression per the given methodology versus progression per the 
given methodology). overall survival rates by LRC were gen-
erated using the Kaplan-Meier method. LRC was then con-
sidered as a variable in multivariate Cox proportional hazards 
models for association with survival.
RESULTS
A total of 1390 patients are included in this analysis. 
Patient characteristics are shown in Table 1. As shown in this 
table, most patients within these RToG trials were relatively 
young (<70 years old), had good performance status, and had 
minimal or no weight loss. Approximately two-thirds of the 
patients were male, and about two-thirds had nonsquamous 
histology. Approximately half of the population had stage II/
IIIA disease and half had IIIB disease.
Analysis of LRC Using FFLP-LRC Methodology
As shown in Figure 1, FFLP-LRC quickly drops from 
100% at time 0 to 63% at 1 year, 44% at 2 years, 38% at 
3 years, and 32% at 5 years. The median duration of FFLP-
LRC was 18.8 months. In the multivariate model, gender 
(p = 0.0002), performance status (p = 0.04), chemotherapy 
sequencing (p = 0.01), and BED (p <0.0001) were associated 
with FFLP-LRC.
Analysis of LRC Using Strict-LRC Methodology
As shown in Figure 2, only 46% of all patients achieved 
at least a partial response to chemoradiotherapy (thus strict-
LRC was 46% at day 1). Strict-LRC dropped to 28% at 
1 year, 17% at 2 years, 14% at 3 years, and 8% at 5 years. 
Age (p = 0.04), performance status (p = 0.04), chemotherapy 
sequencing (p = 0.008), and BED (p = 0.001) were associated 
with strict-LRC in the multivariate analysis.
Association between LRC and Survival  
(FFLP-LRC Methodology)
FFLP-LRC was significantly associated with  overall 
survival. The median survival for patients who achieved 
 FFLP-LRC was 18.1 months (2-year survival 41%, 3-year 
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survival 32%, and 5-year survival 26%), compared with 
16.4-month median survival for patients who suffered 
 local-regional failure by the FFLP-LRC definition (2-year 
survival 33%, 3-year survival 19%, and 5-year survival 8%) 
(p < 0.0001). This is displayed graphically in Figure 3. The 
overall hazard ratio for death based on FFLP-LRC status was 
1.43 (95% confidence interval: 1.28–1.61).
on multivariate Cox model analysis, FFLP-LRC 
remained significantly associated with overall survival (p 
< 0.0001) (Table 2). other factors that were significantly 
associated with overall survival in this model were age 
(70 versus >70; p = 0.004); KPS (90-100 versus 70-80; 
p = 0.005), chemotherapy sequencing (concurrent ver-
sus sequential; p = 0.04), and radiotherapy dose intensity 
delivered (BED as a continuous variable; p < 0.0001). 
Gender and stage were not associated with overall 
survival.
Association between LRC and Survival (Strict-
LRC Methodology)
Strict-LRC was significantly associated with over-
all survival (Table 2). The median survival for patients who 
achieved strict-LRC was 20.9 months (2-year survival 46%, 
3-year survival 38%, and 5-year survival 26%), compared 
with 16.3-month median survival for patients who suffered 
local-regional failure by the strict-LRC definition (2-year 
survival 35%, 3-year survival 22%, and 5-year survival 12%) 
(p < 0.0001). This is displayed graphically in Figure 3. The 
overall hazard ratio for death based on strict-LRC status was 
1.57 (95% confidence interval: 1.36–1.82).
on multivariate Cox model analysis, strict-LRC remained 
significantly associated with overall survival (p < 0.0001). 
Table 1. Pretreatment Characteristics
n=1390
Age
Mean 60.4
Median 61
Range 31  84
 70 1066 (77%)
> 70 324 (23%)
Gender
Male 907 (65%)
Female 483 (35%)
Race
White 1125 (81%)
Hispanic 15 (1%)
Black 123 (9%)
other/unknown 30 (2%)
Not collected 97 (7%)
KPS
90-100 1066 (77%)
70-80 324 (23%)
Weight loss
 5% 1287 (93%)
> 5% 70 (5%)
Unknown 33 (2%)
Histology
Squamous 527 (38%)
Non-squamous 863 (62%)
Stage
II/IIIA 717 (52%)
IIIB 673 (48%)
T-stage
T0T2 687 (49%)
T3T4 691 (50%)
Unknown 12 (1%)
BED n 5 1257
Mean 73.5
Median 74.7
Range 1.386.4
KPS,Karnofskyperformancestatus;BED,biologicallyequivalentdose.
FIGURE 1. Freedom from local progression (FFLP-LRC) for 
all patients (n = 1390).
FIGURE 2. Response-mandatory local-regional control 
(strict-LRC) for all patients (n = 1390).
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other factors that were significantly associated with overall sur-
vival in this model were age ([ltequ]70 versus >70; p = 0.01), 
gender (female versus male; p = 0.05), KPS (90-100 versus 
70-80; p = 0.02), histology (nonsquamous versus squamous; p 
= 0.02), chemotherapy sequencing (concurrent versus sequen-
tial; p = 0.02), and radiotherapy dose intensity delivered (BED 
as a continuous variable; p < 0.0001).
DISCUSSION
our study shows that LRC after chemoradiotherapy for 
stage III NSCLC is suboptimal. Using the traditional FFLP-
LRC definition, the 5-year LRC probability was 32%, and 
using the more rigorous strict-LRC definition local control, the 
5-year LRC probability was 8%. Unlike studies conducted by 
the RToG and others in the 1970s to 1980s, which suggested 
local control rates of about 50%, these more modern trials 
used rigorous CT scan-based assessment of response and local 
control. The results of our study are similar to those reported 
by LeChevalier, in which patients were required to undergo 
postradiotherapy biopsy to assess local disease status.
However, none of these trials used the modern state-
of-the-art technique for assessment of NSCLC status, fluo-
rodeoxyglucose-positron emission tomography (FDG-PET) 
scan, which has shown value for the staging and follow-up of 
patients with stage III NSCLC,12 as reviewed by Mac Manus.
It should also be noted that since these RToG studies 
have been completed, there have been considerable improve-
ments in three-dimensional radiotherapy planning and 
delivery.13-15 It is possible that modern results of chemoradio-
therapy are better than we found here; future rigorous analyses 
of patterns of failure are needed as data mature.
The difference in the numerical rates of LRC depending 
upon the definition of LRC is not surprising. The strict-LRC 
definition not only requires the absence of progressive tumor 
within the radiation field but also requires evidence of an objec-
tive response (50% reduction in the product of two dimensions 
of the dominant tumor mass for measurable disease, as per 
RECIST criteria). It is quite possible that even more dramatic 
differences could be observed if central review of response and 
LRC was performed; unfortunately, the RToG has not had suf-
ficient resources to perform this type of rigorous central review 
in its lung cancer studies. The lack of central review of response 
and LRC is a shortcoming of this current analysis.
Nonetheless, regardless of the methodology used to 
 calculate LRC rates, there is a very strong association between 
LRC and survival. This is axiomatic—it is biologically 
FIGURE 3. Overall survival in patients with (solid lines) or 
without (dashed lines) local control as defined by the FFLP-
LRC or strict-LRC definitions.
Table 2. Multivariate Cox Proportional Hazards Models of Overall Survival
Model Covariate Comparison Hazard Ratioa 95% CI pb
LRC endpoint = freedom from local 
progression (FFLP-LRC)
FFLP-LRC No failure vs. failure 1.42 (1.261.60) <0.0001
Age < 70 vs. > 70 1.29 (1.091.53) 0.004
KPS 90, 100 vs. 70, 80 1.22 (1.061.40) 0.005
Chemotherapy order Concurrent vs. Sequential 1.15 (1.011.32) 0.04
BED Continuous 0.97 (0.960.98) <0.0001
LRC endpoint = response-mandatory  
local-regional control (strict-LRC)
strict-LRC No failure vs. failure 1.49 (1.281.73) <0.0001
Age < 70 vs. > 70 1.24 (1.051.47) 0.01
Gender Female vs. Male 1.14 (1.001.29) 0.047
KPS 90, 100 vs. 70, 80 1.17 (1.021.35) 0.02
Histology Non-squamous vs. squamous 1.15 (1.021.30) 0.02
Chemotherapy order Concurrent vs. sequential 1.17 (1.021.33) 0.02
BED Continuous 0.97 (0.960.98) <0.0001
A stepwise model was used with the following covariates : LRC endpoint (no failure vs. failure), age ( 70 vs.  70), gender (female vs. male), KPS (90, 100 vs. 70, 80), histology 
(non-squamous vs. squamous), AJCC stage grouping (II/IIIA vs. IIIB), chemotherapy order (concurrent vs. sequential) and BED (continuous or cut at the median (74.67353)). The 
entry criterion was p  0.05, and the exit criterion was p-value  0.05.  only covariates in the final model are listed.
aA hazard ratio greater than 1 indicates an increased risk of death for the second level listed.  The hazard ratio for continuous BED indicates how much risk is decreased for each 
increase by 1 in BED.
bLog-rank 2 test
KPS, Karnofsky performance status; BED, biologically equivalentdose.
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implausible to believe that a lung cancer patient can survive 
for very long without achieving control of his or her local 
tumor, irrespective of the occurrence of distant metastases. It 
is interesting to note, however, that the magnitude of the dif-
ference in median survival between patients locally controlled 
and those not locally controlled was modest (18.3 versus 16.9 
months using FFLP-LRC definition; 23. versus 17.0 months 
using strict-LRC definition).
The association between LRC and survival as mea-
sured in this study is not perfect. This is related to several 
factors. First is the high likelihood and lethality of distant 
metastases in this patient population. A second factor may 
be the use of “salvage” chemotherapy. A third and poten-
tially more important factor, however, may be the limita-
tions in our ability to determine LRC, including differences 
in how individual radiation oncologists/investigators assess 
and score LRC and progression. Some patients thought to 
have persistent/recurrent cancer might actually have exu-
berant inflammatory and/or fibrotic tissue after chemora-
diotherapy. other patients thought to have had complete 
response of their cancer may actually have microscopic yet 
highly virulent foci of residual disease. It is possible that the 
use of more sophisticated means to assess the viability of a 
posttreatment mass could provide better information about 
the relationship between local control and survival than 
current means. Studies suggest that FDG-PET scan after 
radiotherapy may be more informative than other methods 
of follow-up.16,17
Factors associated with a higher likelihood of LRC 
and survival did depend on the methodology used. Using 
the FFLP-LRC model, LRC was associated with KPS, che-
motherapy sequencing (concurrent was better), and BED. 
Using the strict-LRC model, KPS, chemotherapy sequenc-
ing, and BED remained important; age was also found to 
be significant. The finding that BED was strongly associ-
ated with LRC is highly relevant to current and future tri-
als of radiotherapy dose escalation and has been analyzed 
in further detail in a separate RToG manuscript by our 
group.18
The details of the association between LRC and sur-
vival also appeared to depend on the definition used for LRC. 
This is evident from visual analysis of the curves in Figures 3 
and 4. Figure 3 shows the relationship between LRC and sur-
vival using the FFLP-LRC definition; although the difference 
is highly statistically significant, there is not a large differ-
ence in the curves until after the first year of follow-up. This 
suggests that FFLP-LRC is not particularly useful as an early 
marker of long-term survival. In contrast, the strong relation-
ship between strict-LRC and survival (Figure 3) becomes 
clear within the first few months of follow-up. Thus, strict-
LRC rates might be a useful surrogate end point for survival 
in future studies of novel treatment regimens. This might be 
particularly true if future study populations are enriched by 
improvements in pretreatment staging (i.e., excluding patients 
with distant metastases identified by PET and/or other means). 
A currently active collaborative trial between the American 
College of Radiology Imaging Network (ACRIN) and the 
RToG is rigorously testing this concept. Specifically, this 
protocol (ACRIN 6668/RToG 0235) is collecting pre- and 
posttreatment FDG-PET scans for analysis of standardized 
uptake value as an imaging-based early marker of long-term 
survival. If this study is positive, future trials of novel agents 
plus radiotherapy for stage III NSCLC may consider using 
response/LRC as a surrogate end point for survival.
CONCLUSIONS
In summary, this analysis reveals that LRC rates are sub-
optimal after standard chemoradiotherapy. The exact results 
depend on the definition of LRC; however, regardless of the 
definition, there is a strong association between LRC and sur-
vival in locally advanced NSCLC.
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